Net Loss of OneSource Specialty Pharma reported to Rs 88.70 crore in the quarter ended December 2025 as against net loss of Rs 68.85 crore during the previous quarter ended December 2024. Sales declined 26.04% to Rs 290.34 crore in the quarter ended December 2025 as against Rs 392.56 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales290.34392.56 -26 OPM %5.9736.14 - PBDT-16.28102.78 PL PBT-85.9234.02 PL NP-88.70-68.85 -29 Powered by Capital Market - Live News

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 23 January 2026.Powered by Capital Market - Live News

OneSource Specialty Pharma has allotted 23,000 equity shares under ESOP on 09 December 2025. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs 11,45,62,136/- (constituting of 11,45,62,136 equity shares of Re 1/- each) to Rs 11,45,85,136/- (constituting of 11,45,85,136 equity shares of Re 1/- each). Powered by Capital Market - Live News

Net profit of OneSource Specialty Pharma reported to Rs 10.49 crore in the quarter ended September 2025 as against net loss of Rs 42.08 crore during the previous quarter ended September 2024. Sales rose 12.49% to Rs 375.76 crore in the quarter ended September 2025 as against Rs 334.05 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales375.76334.05 12 OPM %28.3423.14 - PBDT75.5736.65 106 PBT5.74-31.63 LP NP10.49-42.08 LP Powered by Capital Market - Live News

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live News